Prescient Therapeutics has dosed the last patient in the escalation stage of its Akt inhibition phase Ib breast cancer trial, targeting women with metastatic and locally advanced HER2 negative breast cancer.
The H. Lee Moffitt Cancer Center in Tampa, Florida will shortly join Albert Einstein University in the phase Ib expansion cohort and the phase II trial, and is expected to soon commence recruitment.
Dr Heather Han, a medical oncologist specialising in breast cancer in The Center for Women's Oncology at Moffitt, will conduct the study.
Share
